Benign prostatic hyperplasia is considered a progressive disease intimately linked with aging.
The long-term use of combination therapy with a 5-alpha-reductase inhibitor, together with an alpha blocker in men with moderate-severe symptoms, reduces the risk of clinical progression and BPH-related surgery. It is unclear what the impact is of preoperative therapy with 5-ARI in patients that undergo surgery. The aim of our study was to evaluate the impact of preoperative therapy with 5-alpha-reductase inhibitors on: a) indication on the type of surgery; b) surgical and functional outcomes; c) surgical complications. This is a prospective observational study. It will include all patients undergoing surgery by TURP or Open Prostatectomy in a period of 24 months. We expect results that demonstrate significant and favorable influence of pretreatment with 5-alpha-reductase inhibitors on certain outcomes. Therefore, therapy with 5-ARI could be considered as neoadjuvant to surgery, whatever this is.
Written by:
De Stefano G, Fusco F, Arcaniolo D, Pistone A, Capece M, Sannino S, Mirone V. Are you the author?
Clinica urologica, Università Federico II, Napoli, Italy.
Reference: Urologia. 2012 Apr-Jun;79(2):149-51.
doi: 10.5301/RU.2012.9277
PubMed Abstract
PMID: 22610839
Article in Italian.
